Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

Atsuhiro Morita; Nobuharu Tamaki; Haruhiko Kobashi; Nami Mori; Keiji Tsuji; Shintaro Takaki; Chitomi Hasebe; Takehiro Akahane; Hironori Ochi; Toshie Mashiba; Naohito Urawa; Hideki Fujii; Akeri Mitsuda; Masahiko Kondo; Chikara Ogawa; Yasushi Uchida; Ryoichi Narita; Hiroyuki Marusawa; Yoshihito Kubotsu; Tomomichi Matsushita; Masaya Shigeno; Hideo Yoshida; Katsuaki Tanaka; Eisuke Okamoto; Toyotaka Kasai; Toru Ishii; Kazuhiko Okada; Masayuki Kurosaki; Namiki Izumi

doi:10.1002/jgh3.13068

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study

JGH Open. 2024 Apr 25;8(4):e13068. doi: 10.1002/jgh3.13068. eCollection 2024 Apr.

Authors

Atsuhiro Morita¹, Nobuharu Tamaki², Haruhiko Kobashi³, Nami Mori⁴, Keiji Tsuji⁴, Shintaro Takaki⁴, Chitomi Hasebe⁵, Takehiro Akahane⁶, Hironori Ochi⁷, Toshie Mashiba⁷, Naohito Urawa⁸, Hideki Fujii⁹, Akeri Mitsuda¹⁰, Masahiko Kondo¹¹, Chikara Ogawa¹², Yasushi Uchida¹³, Ryoichi Narita¹⁴, Hiroyuki Marusawa¹⁵, Yoshihito Kubotsu¹⁶, Tomomichi Matsushita¹⁷, Masaya Shigeno¹⁸, Hideo Yoshida¹⁹, Katsuaki Tanaka²⁰, Eisuke Okamoto²¹, Toyotaka Kasai²², Toru Ishii²³, Kazuhiko Okada²⁴, Masayuki Kurosaki², Namiki Izumi²

Affiliations

¹ Department of Gastroenterology Japanese Red Cross Kyoto Daini Hospital Kyoto Japan.
² Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.
³ Department of Gastroenterology Japanese Red Cross Okayama Hospital Okayama Japan.
⁴ Department of Gastroenterology Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima Japan.
⁵ Department of Gastroenterology Japanese Red Cross Asahikawa Hospital Asahikawa Japan.
⁶ Department of Gastroenterology Ishinomaki Red Cross Hospital Ishinomaki Japan.
⁷ Center for Liver-Biliary-Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan.
⁸ Department of Gastroenterology and Hepatology Ise Red Cross Hospital Ise Japan.
⁹ Department of Gastroenterology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan.
¹⁰ Department of Gastroenterology Tottori Red Cross Hospital Tottori Japan.
¹¹ Department of Gastroenterology Otsu Red Cross Hospital Otsu Japan.
¹² Department of Gastroenterology and Hepatology Takamatsu Red Cross Hospital Takamatsu Japan.
¹³ Department of Gastroenterology Matsue Red Cross Hospital Matsue Japan.
¹⁴ Department of Gastroenterology Oita Red Cross Hospital Oita Japan.
¹⁵ Department of Gastroenterology and Hepatology Osaka Red Cross Hospital Osaka Japan.
¹⁶ Department of Internal Medicine Karatsu Red Cross Hospital Saga Japan.
¹⁷ Department of Gastroenterology Japanese Red Cross Gifu Hospital Gifu Japan.
¹⁸ Department of Gastroenterology Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki Japan.
¹⁹ Department of Gastroenterology Japanese Red Cross Medical Center Tokyo Japan.
²⁰ Department of Gastroenterology Hatano Red Cross Hospital Hatano Japan.
²¹ Department of Gastroenterology Masuda Red Cross Hospital Masuda Japan.
²² Department of Gastroenterology Fukaya Red Cross Hospital Saitama Japan.
²³ Department of Gastroenterology Japanese Red Cross Akita Hospital Akita Japan.
²⁴ Department of Gastroenterology Toyama Red Cross Hospital Toyama Japan.

Abstract

Background and aim: In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non-cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of treatment for cirrhosis may reduce treatment efficacy has not been adequately investigated.

Methods: This prospective, nationwide, multicenter cohort study enrolled 1275 patients with chronic hepatitis C who received GLE/PIB therapy. The effect of liver fibrosis and treatment periods on the efficiency of GLE/PIB therapy was investigated. The primary endpoint was the sustained virological response (SVR) rate in patients with chronic hepatitis (non-cirrhosis) and cirrhosis. The association between treatment periods and liver fibrosis on the SVR after 12 weeks of treatment rate was investigated.

Results: The SVR rates in patients with chronic hepatitis with 8 weeks of treatment, chronic hepatitis with 12 weeks of treatment, cirrhosis with 8 weeks of treatment, and cirrhosis with 12 weeks of treatment were 98.9% (800/809), 100% (87/87), 100% (166/166), and 99.1% (211/213), respectively, and were was not different among these groups (P = 0.4).

Conclusion: GLE/PIB therapy for chronic hepatitis C had high efficacy regardless of liver fibrosis status and treatment periods. Periods of GLE/PIB therapy could be chosen with available modalities, and high SVR rates could be achieved regardless of the decision.

Keywords: chronic hepatitis C; cirrhosis; glecaprevir and pibrentasvir (GLE/PIB); treatment periods.